Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA Bacteremia

Journal of Infection

Volumn 61, Issue 5, 2010, Pages 372-381

  Kempker, Russell R ^a   Farley, Monica M ^a,b,c   Ladson, Janine L ^c   Satola, Sarah ^a,b,c   Ray, Susan M ^a,c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c Georgia Emerging Infections Program   (United States)

^d GRADY MEMORIAL HOSPITAL   (United States)

Author keywords

Community associated; Methicillin resistant; Staphylococcus aureus; USA300

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BACTERIAL VIRULENCE; CHILD; COMMUNICABLE DISEASE; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; FEMALE; GENOTYPE; HOSPITAL INFECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NEGRO; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; STRAIN DIFFERENCE;

ADOLESCENT; ADULT; AGED; BACTEREMIA; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; CROSS INFECTION; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; GENOTYPE; GEORGIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RISK FACTORS; SENTINEL SURVEILLANCE; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 78149359509     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.09.021     Document Type: Article

References (43)

1. Shorr A.F., Tabak Y.P., Killian A.D., Gupta V., Liu L.Z., Kollef M.H. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006, 34(10):2588-2595.
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317.
3. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Assoc 2007, 298(15):1763-1771.
4. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. JAMA 1999, 282(12):1123-1125. From the Centers for Disease Control and Prevention.
5. Baggett H.C., Hennessy T.W., Rudolph K., Bruden D., Reasonover A., Parkinson A., et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004, 189(9):1565-1573.
6. Kazakova S.V., Hageman J.C., Matava M., Srinivasan A., Phelan L., Garfinkel B., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005, 352(5):468-475.
7. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003, 52(5):88.
8. Adcock P.M., Pastor P., Medley F., Patterson J.E., Murphy T.V. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis 1998, 178(2):577-580.
9. Zinderman C.E., Conner B., Malakooti M.A., LaMar J.E., Armstrong A., Bohnker B.K. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004, 10(5):941-944.
10. Diep B.A., Chambers H.F., Graber C.J., Szumowski J.D., Miller L.G., Han L.L., et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008, 148(4):249-257.
11. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290(22):2976-2984.
12. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. N Engl J Med 2006, 355(7):666-674.
13. McDougal L.K., Steward C.D., Killgore G.E., Chaitram J.M., McAllister S.K., Tenover F.C. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003, 41(11):5113-5120.
14. Seybold U., Kourbatova E.V., Johnson J.G., Halvosa S.J., Wang Y.F., King M.D., et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006, 42(5):647-656.
15. Klevens R.M., Morrison M.A., Fridkin S.K., Reingold A., Petit S., Gershman K., et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare risk factors. Emerg Infect Dis 2006, 12(12):1991-1993.
16. Diep B.A., Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol 2008, 16(8):361-369.
17. Hosmer D.W., Lemeshow S., May S. Applied survival analysis: regression modeling of time-to-event data. Model development 2008, Wiley-Interscience. 2nd ed.
18. Soriano A., Martinez J.A., Mensa J., Marco F., Almela M., Moreno-Martinez A., et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000, 30(2):368-373.
19. Kaech C., Elzi L., Sendi P., Frei R., Laifer G., Bassetti S., et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006, 12(4):345-352.
20. Wang R., Braughton K.R., Kretschmer D., Bach T.H., Queck S.Y., Li M., et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007, 13(12):1510-1514.
21. Li M., Diep B.A., Villaruz A.E., Braughton K.R., Jiang X., DeLeo F.R., et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A 2009, 106(14):5883-5888.
22. Voyich J.M., Braughton K.R., Sturdevant D.E., Whitney A.R., Said-Salim B., Porcella S.F., et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 2005, 175(6):3907-3919.
23. Cremieux A.C., Dumitrescu O., Lina G., Vallee C., Cote J.F., Muffat-Joly M., et al. Panton-valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 2009, 4(9):e7204.
24. Labandeira-Rey M., Couzon F., Boisset S., Brown E.L., Bes M., Benito Y., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315(5815):1130-1133.
25. Chambers H.F., Deleo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7(9):629-641.
26. Conterno L.O., Wey S.B., Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998, 19(1):32-37.
27. Kim S.H., Park W.B., Lee K.D., Kang C.I., Kim H.B., Oh M.D., et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003, 37(6):794-799.
28. Shurland S., Zhan M., Bradham D.D., Roghmann M.C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007, 28(3):273-279.
29. Laupland K.B., Ross T., Gregson D.B. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008, 198(3):336-343.
30. Burton D.C., Edwards J.R., Horan T.C., Jernigan J.A., Fridkin S.K. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009, 301(7):727-736.
31. Bagger J.P., Zindrou D., Taylor K.M. Postoperative infection with meticillin-resistant Staphylococcus aureus and socioeconomic background. Lancet 2004, 363(9410):706-708.
32. Huggan P.J., Wells J.E., Browne M., Richardson A., Murdoch D.R., Chambers S.T. Population-based epidemiology of Staphylococcus aureus bloodstream infection in Canterbury, New Zealand. Intern Med J 2009.
33. Burkey M.D., Wilson L.E., Moore R.D., Lucas G.M., Francis J., Gebo K.A. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med 2008, 9(10):858-862.
34. Hidron A.I., Kourbatova E.V., Halvosa J.S., Terrell B.J., McDougal L.K., Tenover F.C., et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005, 41(2):159-166.
35. Shet A., Mathema B., Mediavilla J.R., Kishii K., Mehandru S., Jeane-Pierre P., et al. Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. J Infect Dis 2009, 200(1):88-93.
36. Pos O., Stevenhagen A., Meenhorst P.L., Kroon F.P., Van Furth R. Impaired phagocytosis of Staphylococcus aureus by granulocytes and monocytes of AIDS patients. Clin Exp Immunol 1992, 88(1):23-28.
37. Schaumann R., Krosing J., Shah P.M. Phagocytosis of Escherichia coli and Staphylococcus aureus by neutrophils of human immunodeficiency virus-infected patients. Eur J Med Res 1998 Dec 16, 3(12):546-548.
38. Gould F.K., Brindle R., Chadwick P.R., Fraise A.P., Hill S., Nathwani D., et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009 May, 63(5):849-861.
39. Corey G.R. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis 2009 May 15, 48(4):S254-259.
40. Kim S.H., Park W.B., Lee K.D., Kang C.I., Bang J.W., Kim H.B., et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004 Aug, 54(2):489-497.
41. Fang C.T., Shau W.Y., Hsueh P.R., Chen Y.C., Wang J.T., Hung C.C., et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006 Mar, 57(3):511-519.
42. Kim S.H., Park W.B., Lee C.S., Kang C.I., Bang J.W., Kim H.B., et al. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect 2006 Jan, 12(1):13-21.
43. Ammerlaan H., Seifert H., Harbarth S., Brun-Buisson C., Torres A., Antonelli M., et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009 Oct 1, 49(7):997-1005.